N
40.00
-31.53 (-44.08%)
| Previous Close | 71.53 |
| Open | 48.28 |
| Volume | 1,989,666 |
| Avg. Volume (3M) | 135,914 |
| Market Cap | 593,144,000 |
| Price / Sales | 957.83 |
| Price / Book | 5.72 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2024 - 26 Nov 2024 |
| Operating Margin (TTM) | -2,176.65% |
| Diluted EPS (TTM) | -3.66 |
| Total Debt/Equity (MRQ) | 8.89% |
| Current Ratio (MRQ) | 12.17 |
| Operating Cash Flow (TTM) | -66.08 M |
| Levered Free Cash Flow (TTM) | -34.07 M |
| Return on Assets (TTM) | -32.36% |
| Return on Equity (TTM) | -41.34% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Neurogene Inc. | Bullish | - |
Stockmoo Score
0.4
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.38 |
|
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today’s complex devastating neurological diseases into treatable conditions. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 10.69% |
| % Held by Institutions | 103.11% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 72.00 (Leerink Partners, 80.00%) | Buy |
| 72.00 (Baird, 80.00%) | Buy | |
| Median | 60.00 (50.00%) | |
| Low | 45.00 (BMO Capital, 12.50%) | Buy |
| Average | 60.80 (52.00%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 31.93 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BMO Capital | 20 Nov 2024 | 45.00 (12.50%) | Buy | 19.82 |
| 12 Nov 2024 | 60.00 (50.00%) | Buy | 40.00 | |
| HC Wainwright & Co. | 19 Nov 2024 | 55.00 (37.50%) | Buy | 19.82 |
| 12 Nov 2024 | 55.00 (37.50%) | Buy | 40.00 | |
| Baird | 12 Nov 2024 | 72.00 (80.00%) | Buy | 40.00 |
| Leerink Partners | 12 Nov 2024 | 72.00 (80.00%) | Buy | 40.00 |
| Stifel | 12 Nov 2024 | 60.00 (50.00%) | Buy | 40.00 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 18 Nov 2024 | Announcement | Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome |
| 18 Nov 2024 | Announcement | Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates |
| 11 Nov 2024 | Announcement | Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome |
| 04 Nov 2024 | Announcement | Neurogene Announces Oversubscribed $200 Million Private Placement |
| 21 Oct 2024 | Announcement | Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |